The plan to perform the transition of $SDEX to $EV utility token is a landmark development since the official rebranding from SMARDEX to Everything.The plan to perform the transition of $SDEX to $EV utility token is a landmark development since the official rebranding from SMARDEX to Everything.

Everything Introduces $EV as New Core Token Following Rebranding

Everything, a popular decentralized finance (DeFi) protocol, has announced a key move in the ecosystem evolution. In this respect, it is executing the transition from $SDEX to the latest $EV token protocol. This move is the next step of completing its rebranding from SMARDEX to Everything. As per the announcement, this move indicates a broadened transition. Additionally, this transition is inclusive, structured, and gradual for existing participants.

Everything Initiates $SDEX to $EV Migration after Strategic Rebranding from SMARDEX

Particularly, Everything’s plan to perform the transition of $SDEX to $EV is a landmark development since the official rebranding. Everything is a name selected to highlight a more ambitious, wider, and long-term roadmap. By unveiling $EV as an exclusive primary token, the platform attempts to back future growth, a relatively scalable ecosystem structure, and more use cases. Interestingly, the transition pays significant attention to continuity, guaranteeing that the present $SDEX holders are completely onboarded.

To back this procedure, Everything has initiated a couple of initial migration paths that only the existing $SDEX holders, as well as the early participants, can use. The 1st of them is a migration-focused staking project that permits consumers to lock their $SDEX tokens for twelve months for $EV coins. The respective tokens are reportedly fixed at the starting valuation of the token, providing predictability for those who support it in the long run.

Additionally, the 2nd path serves as a community pre-sale mechanism utilizing a merged burn-and-contribution framework. It takes into account the vesting of $EV tokens over an extended timeframe to boost sustained protocol alignment. While discussing this, Everything’s CEO and co-founder, Jean Rausis, pointed out that the transition turns the rebrand into a meaningful value. As per the executive, the $EV pathway rewards long-term commitment and patience instead of short-term speculation.

Fortifying Token Ecosystem through Systematic Migration and Expansion Plans

According to Everything, the latest migration framework carefully avoids abrupt supply shocks along with preserving the utility of $SDEX throughout the transition. Additionally, the participants will get the ability to actively operate within the ecosystem, engage with unique features, and trade $EV and $SDEX. Moreover, the platform anticipates new opportunities and ecosystem expansion to outperform relative dilution with time.

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Trump Filed a Lawsuit Against JPMorgan Chase And Its CEO Over Debanking

Trump Filed a Lawsuit Against JPMorgan Chase And Its CEO Over Debanking

U.S. President Donald Trump filed a lawsuit against JPMorgan Chase and its CEO Jamie Dimon personally, accusing the institution of deliberate debanking. The politician
Share
Incrypted2026/01/23 15:59
Here’s why Polygon price is at risk of a 25% plunge

Here’s why Polygon price is at risk of a 25% plunge

Polygon price continued its freefall, reaching its lowest level since April 21, as the broader crypto sell-off gained momentum. Polygon (POL) dropped to $0.1915, down 32% from its highest point in May and 74% below its 2024 peak. The crash…
Share
Crypto.news2025/06/19 00:56
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26